Radiopharmaceuticals Market Size and Forecast (2021-2031)

Radiopharmaceuticals Market Size and Forecast (2021-2031)

Radiopharmaceuticals Market Size and Forecast (2021 – 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application (Oncology, Cardiology, Neurology, Pulmonary, Urology, and Others), Type (Diagnostic and Therapeutic), Tracer Type (Tc-99m, F-18, Ga-68, TL-201, I-131, Fe-59, Lu-171, RB-82 and N-13, Cr-51 and P-32, Sc-46, Sg-269 and Hs-269, and Others), End User (Hospitals and Clinics, Diagnostic Centers, Academic and Research Institutes, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

Send Enquiry
Item ID: TIPRE00003751 Category: Tag:

$3,633 – $6,433

Description

The radiopharmaceuticals market size is projected to surge from US$ 9.07 billion in 2023 to US$ 26.51 billion by 2031; the market is estimated to record a CAGR of 14.4% during 2023–2031. The rising prevalence of chronic diseases and the growing number of clinical trials in targeted therapy propel the radiopharmaceuticals market growth.

Radiopharmaceuticals have proven to handle the diagnosis and treatment of age-related diseases efficiently. The development of radiopharmaceuticals with improved targeting capabilities, longer half-lives, and fewer side effects makes them more attractive for various applications. Research into theranostics that combine diagnostic and therapeutic functions in a single radiopharmaceutical is promising and could further drive the market growth. As governments across the world recognize the value of radiopharmaceuticals in improving health outcomes, an increase in the funding for research and development of new radiopharmaceuticals and supportive regulatory pathways for their approval has been observed. Further, the market is progressing toward meeting the demands of a changing healthcare landscape, and the evolving radiopharmacy facilities using advanced diagnostic techniques are expected to bring new radiopharmaceuticals market trends in the coming years.

Rising Prevalence of Chronic Diseases Drives the Radiopharmaceuticals Market

Chronic diseases such as lung diseases, cancer, stroke, Alzheimer’s, cardiovascular diseases (CVDs), chronic kidney disease, and various neurological disorders are increasing swiftly across the world. As per the World Health Organization (WHO), in 2020, ~10 million deaths were reported due to cancer globally. Likewise, as per the estimations of the American Cancer Society, in 2020, ~1,806,590 new cases of cancer were diagnosed in the US. As per the National Cancer Registry Program Report 2020, in India, 679,421 cancer cases were reported in males, and the number is anticipated to increase to ~763,575 by 2025; whereas in females, 712,758 cancer cases were recorded in 2020, and the number is predicted to reach 806,218 by 2025. According to the American Cancer Society’s report, in 2023, ~43,720 new cases of thyroid cancer (31,180 in women and 12,540 in men) were recorded. CVDs are among the most prevalent types of chronic diseases that result in a high mortality rate. The Centers for Disease Control and Prevention states that heart disease is the leading cause of death in the US. According to the same source, in 2020, ~697,000 deaths, i.e., 1 in 5 deaths, were caused by heart disease in the US. According to the Parkinson’s Foundation, Parkinson’s symptoms are usually observed in individuals aged 60 years and above. The Canadian Psychological Association states that about 2% of the population in Canada suffers from obsessive-compulsive disorder. As per the WHO, neurological diseases contribute to 6.3% of the global disease burden and are also among the leading causes of death worldwide. 13.2% and 16.8% of deaths are reported due to neurological diseases in developed and low- and middle-income countries, respectively. Radiopharmaceuticals have been demonstrated to have high efficiency in diagnosing neurological and neurodegenerative disorders and musculoskeletal conditions. Radiopharmaceuticals are set apart due to their dual functionality. They not only enhance the visualization of diseases but also provide crucial functional information. Among the various methods available, radioisotope cell labeling is one of the most promising techniques to track cells to investigate their biodistribution. Thus, the surging incidence of chronic diseases is driving the radiopharmaceuticals market growth.

Market Trend

Evolving Radiopharmacy Facilities

Nuclear medicine is a field that is undergoing many changes. As radiopharmaceuticals evolve rapidly, more advanced diagnostic techniques such as PET and radiotherapeutics are becoming more widely used. In low-income countries, the technology is still being established, owing to the efforts by the International Atomic Energy Agency (IAEA), while in some of the technologically advanced countries such as the US, it is evolving into standard care, particularly with the advent of theranostics.

Several African countries are working toward expanding and modernizing their radiopharmaceutical facilities to produce radiopharmaceutical medicines with the help of IAEA’s Technical Cooperation Program and coordinated research projects. For instance, with IAEA’s support, Tunisia, a country in North Africa, started using PET. At the same time, in Algeria, a medical cyclotron was installed and commissioned. The machine enables the country to produce its radiopharmaceuticals and enables routine PET imaging for many types of cancer, such as lymphoma and lung and colon cancer.

The International Symposium on Trends in Radiopharmaceuticals showcases the bright future of radiopharmaceutical chemistry and nuclear medicine. Advances in isotope production, radiochemistry, and the implementation of novel radiopharmaceuticals in human studies lead to exciting results. In particular, theranostic strategies, which use imaging to guide targeted therapy, and the growing areas of research are helping the global nuclear medicine community realize the potential of personalized medicine through the development of new radiotherapeutics. Theranostics merges diagnostics and therapy in a single approach. Radioactive tracers identify specific targets (diagnosis) and then perform targeted therapies. This approach lets physicians personalize treatment plans for patients by assessing their response to therapy in real time. Theranostics are particularly promising for the treatment of certain forms of cancer, such as prostate cancer and neuroendocrine tumors. With new radiotracers and imaging agents, molecular imaging is becoming more specific and sensitive, enabling earlier and more accurate disease detection. In addition, hybrid imaging, such as PET-CT and PET-MRI, combines two or more imaging modalities to provide complementary information and improve diagnostic accuracy. These approaches combine functional and anatomical information, enabling a comprehensive overview of disease processes. Therefore, such developments and approaches are expected to drive the market growth in the future.

The “Global Radiopharmaceuticals Market” is segmented on the basis of application, tracer type, end user, and geography.

Application-Based Insights

Based on application, the radiopharmaceuticals market analysis is carried out by considering the following segments: oncology, cardiology, neurology, pulmonary, urology, and others. The oncology segment held the largest market share in 2023 and is anticipated to register the highest CAGR of 14.8% during the forecast period. Cancer is one of the major health problems with a high mortality rate. As per the WHO, in 2020, an estimated 10.1 million new cancer cases were diagnosed, and 10 million people died from cancer worldwide. The diagnosis and treatment of patients with cancer require access to imaging to ensure accurate management decisions and optimal outcomes. Nuclear medicine therapy is used to treat cancer, and the most common radiotracer is F-18 fluorodeoxyglucose (FDG). FDG is similar to glucose, and cancer cells are more metabolically active; therefore, they absorb glucose at a higher rate. This can be seen on PET scans and thereby allows the healthcare professional to detect the disease. Fluorine-i8 labeled as flurodeoxyglucose is effective in differentiating malignant from benign tumors and in determining the extent of the disease. People with neuroendocrine tumors (NETs) have wider access to PRRT following the FDA approval of lutetium Lu 177 dotatate (Lutathera) in January 2018.

End User-Based Insights

By end user, the market is segmented into hospitals and clinics, diagnostic centers, academic and research institutes, and others. The hospitals and clinics segment dominated the radiopharmaceuticals market share in 2023. The diagnostic centers segment is anticipated to register the highest CAGR of 14.8% during 2023–2031. Hospitals and clinics utilize technologically advanced treatment for cardiac aneurysms, oncology tumors, neurology aneurysms, and other treatment procedures. The growing need for cardiovascular and neurology aneurysm treatments has become one of the major factors driving the market growth for the hospitals and clinics segment. Most of the surgeries are being performed in hospitals, owing to the continuous patient care and monitoring.

US Food and Drug Administration, European Union, World Health Organization, International Atomic Energy Agency, Centers For Disease Control And Prevention, National Cancer Institute, National Medical Products Administration, Organization For Economic Co-Operation And Development, and Canadian Nuclear Safety Commission are some of the relevant sources referred while preparing the radiopharmaceuticals market research report.

Summary Info

Industry:

Pricing options:

, ,

Geographical coverage:

Year of Publication:

Oncology Segment to Lead Global Radiopharmaceuticals Market During 2023–2031

According to our latest study on “Radiopharmaceuticals Market Forecast to 2031 – Global Analysis – Application, Type, Tracer Type, End User, and Geography,” the market is expected to reach US$ 26.51 billion by 2031 from US$ 9.07 billion in 2023; it is estimated to register a CAGR of 14.4% from 2023 to 2031. The report emphasizes the key factors driving the market and the developments of prominent players. Factors such as the increasing prevalence of chronic diseases and the growing number of clinical trials propel the market growth.

Radiopharmaceuticals are biological molecules tagged with radioisotopes, which target specific tissues, organs, or cells within the human body. Radioisotopes emitting gamma rays are used in diagnostic imaging. Radiopharmaceuticals can help in targeting various malignancies such as prostate cancer, heart disease, and thyroid cancer. In recent years, radiopharmaceuticals have become one of the most effective techniques in various fields, including neurology, cardiology, and oncology. Each radiopharmaceutical targets a specific area in the body and releases radioactive substances to attack tumor cells once it reaches its location. Researchers have identified radiopharmaceuticals that can work against tumors such as thyroid carcinoma, brain tumors, lymphoma, and bone cancer. Traditional chemotherapy methods for cancer treatment are replaced with more practical therapeutic radiopharmaceuticals, opening up new market opportunities. Compared to X-rays and other external radiation imaging systems, radiopharmaceuticals assist doctors in diagnosing and providing a convenient and safer alternative for patients. Radiopharmaceuticals that are used for diagnostic purposes are called tracers. The amount of radiation released from diagnostic radiopharmaceuticals is lower than that of therapeutic radiopharmaceuticals. Developments in medical imaging technology, increasing rates of chronic diseases, and growing emphasis on personalized therapy contribute to the significant growth of the radiopharmaceuticals market. Nuclear medicine relies heavily on radiopharmaceuticals that are produced from radioisotopes bound to drugs, enabling imaging and treatment of various diseases.

The rising incidence of cancer and increasing application in the treatment of cardiovascular disorders drive the radiopharmaceuticals market growth. However, regulatory challenges for the approval of radioisotopes hamper the growth of the radiopharmaceuticals market.

Based on type, the market is bifurcated into diagnostic and therapeutic. The diagnostic segment held a larger radiopharmaceuticals market share in 2023 and is anticipated to register a higher CAGR during 2023–2031. Radiopharmaceuticals are used to form images of organs or tissues needed. The gamma camera detects the gamma rays produced by the radioisotope. It generates images in a non-invasive manner that reflects the functioning of organs or tissues under investigation. In March 2022, Novartis announced approval for “Pluvicto” (lutetium Lu 177 vipivotide tetraxetan) for treating adult patients suffering from a certain type of advanced cancer, i.e., prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer. The approval of the product can significantly improve survival rates for patients with limited treatment options, and product approval is a new step in the evolution of precision medicine to treat prostate cancer. Companies such as Advanced Accelerator Applications and IASON GmbH offer radiopharmaceuticals for diagnosis using PET scanners, single photon emission computed tomography (SPECT) scanners, alpha emitters, and others.

By end user, the market is segmented into hospitals and clinics, diagnostic centers, academic and research institutes, and others. The hospitals and clinics segment dominated the radiopharmaceuticals market share in 2023. The diagnostic centers segment is anticipated to register the highest CAGR of 14.8% during 2023–2031.

Global Radiopharmaceuticals Market, by End User, 2023 & 2031 (%)

Source: the Research Team Analysis

High Growth Potential in Developing Countries

Many medical market players focus on emerging countries in Asia, South America, and Africa due to a rise in the prevalence of various diseases in these regions. The medical field in India is growing rapidly, and it has undergone several significant changes over the last few decades. In April 2019, ITM Isotopen Technologien München AG (ITM) and United Imaging Healthcare Co., Ltd. (UIH) signed an agreement to collaborate for the commercialization of ITM and UIH imaging products, along with other related products, in the clinical market in China and other countries across the world. Further, the prevalence of CVDs is rising significantly in developing nations, which can be mainly attributed to the shift in lifestyle as well as the adoption of modern facilities. The modernization of residential, corporate, and commercial facilities is leading to a reduction in physical activities, while stress levels are continuously on the rise due to various factors related to livelihood. These conditions may trigger the possibility of developing CVDs among people, thus boosting the demand for various imaging instruments, including nuclear imaging techniques. Research organizations in developing countries are engaged in the development of advanced diagnosis systems, including cost-effective and high-performance PET/SPECT systems. These developments are mainly aimed at extending their reach to remote areas where advanced medical IT facilities are not accessible. China, Japan, and Brazil, among other emerging countries, are spending heavily on the development of PET/SPECT machines to lower their costs and offer hospitals and other medical organizations better access to these machines.

Countries in Asia Pacific, Latin America, and the Mediterranean region are significant targets for the companies to set up their financial operations and increase revenue generation through strategic planning such as mergers and acquisitions. In March 2021, BWXT Medical Ltd. and Global Medical Solutions, Ltd. (GMS) entered into a joint venture to manufacture and distribute radioisotopes and radiopharmaceuticals in Asia Pacific. Thus, developing countries are offering significant opportunities to the radiopharmaceuticals market players to expand their reach and clientele.

Medi-Radiopharma (MRP), Rotem Industries Ltd., ABX Advanced Biochemical Compounds GmbH, Invicro LLC, Cardinal Health, Newcastle University, Novartis, Curium, Blue Earth Diagnostics, General Electric Company, and IBA Radiopharma Solutions are among the leading companies operating in the global radiopharmaceuticals market.

Based on geography, the radiopharmaceuticals market is segmented into the North America (United States, Canada, and Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), South & Central America (Brazil, Argentina, and Rest of South & Central America), and Middle East & Africa (Saudi Arabia, South Africa, UAE, and Rest of Middle East & Africa).

North America holds a dominant share in the radiopharmaceuticals market. The market growth in this region is due to increasing incidences of chronic diseases, supportive government plans, growing strategic initiatives by the market players, and development of innovative radiotherapies. The US holds the largest share of the radiopharmaceuticals market in North America. The market is expected to grow owing to the availability of advanced healthcare infrastructure, rising incidence and prevalence of target conditions, and product innovations by key players operating in the region. Also, innovative products have been launched by the players operating in the market to offer better treatment. For instance, in September 2022, MD Anderson Cancer Center and Radiopharm Theranostics launched Radiopharm Ventures, LLC, a joint venture for developing novel radiopharmaceutical therapeutic products for cancer.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the global radiopharmaceuticals market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the global radiopharmaceuticals market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth market trends and outlook in regional market coupled with the factors driving the market, as well as those hindering it.
o Enhancing the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Radiopharmaceuticals Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Pricing Analysis
4.3.1 Regional Pricing Analysis, US$ (Per Dose)
5. Radiopharmaceuticals Market – Key Market Dynamics
5.1 Radiopharmaceuticals Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Prevalence of Chronic Diseases
5.2.2 Growing Number of Clinical Trials in Targeted Therapy
5.3 Market Restraints
5.3.1 Short Shelf-Life of Radiopharmaceuticals
5.4 Market Opportunities
5.4.1 High Growth Potential in Developing Countries
5.5 Future Trends
5.5.1 Evolving Radiopharmacy Facilities
5.6 Impact of Drivers and Restraints:
6. Radiopharmaceuticals Market – Global Market Analysis
6.1 Radiopharmaceuticals Market Revenue (US$ Million), 2023–2031
7. Radiopharmaceuticals Market Analysis – by Application
7.1 Overview
7.2 Oncology
7.2.1 Overview
7.2.2 Oncology: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Cardiology
7.3.1 Overview
7.3.2 Cardiology: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Neurology
7.4.1 Overview
7.4.2 Neurology: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Pulmonary
7.5.1 Overview
7.5.2 Pulmonary: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
7.6 Urology
7.6.1 Overview
7.6.2 Urology: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
8. Radiopharmaceuticals Market Analysis – by Type
8.1 Overview
8.2 Diagnostic
8.2.1 Overview
8.2.2 Diagnostic: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
8.2.2.1 Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – By Diagnostic
8.3 Therapeutic
8.3.1 Overview
8.3.2 Therapeutic: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
8.3.2.1 Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – By Therapeutic
9. Radiopharmaceuticals Market Analysis – by Tracer Type
9.1 Overview
9.2 Tc-99m
9.2.1 Overview
9.2.2 Tc-99m: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.2.2.1 Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – By Tc-99m
9.3 F-18
9.3.1 Overview
9.3.2 F-18: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.4 Ga-68
9.4.1 Overview
9.4.2 Ga-68: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.5 TL-201
9.5.1 Overview
9.5.2 TL-201: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.6 I-131
9.6.1 Overview
9.6.2 I-131: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.7 Fe-59
9.7.1 Overview
9.7.2 Fe-59: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.8 Lu-171
9.8.1 Overview
9.8.2 Lu-171: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.9 RB-82 and N-13
9.9.1 Overview
9.9.2 RB-82 and N-13: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.10 Cr-51 and P-32
9.10.1 Overview
9.10.2 Cr-51 and P-32: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.11 Sc-46
9.11.1 Overview
9.11.2 Sc-46: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.12 Sg-269 and Hs-269
9.12.1 Overview
9.12.2 Sg-269 and Hs-269: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
9.13 Others
9.13.1 Overview
9.13.2 Others: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
10. Radiopharmaceuticals Market Analysis – by End User
10.1 Overview
10.2 Hospitals and Clinics
10.2.1 Overview
10.2.2 Hospitals and Clinics: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
10.3 Diagnostic Centers
10.3.1 Overview
10.3.2 Diagnostic Centers: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
10.4 Academic and Research Institutes
10.4.1 Overview
10.4.2 Academic and Research Institutes: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
10.5 Others
10.5.1 Overview
10.5.2 Others: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11. Radiopharmaceuticals Market – Geographical Analysis
11.1 Overview
11.2 North America
11.2.1 North America Radiopharmaceuticals Market Overview
11.2.2 North America: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.2.3 North America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Application
11.2.4 North America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Type
11.2.4.1 North America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Diagnostic
11.2.4.2 North America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Therapeutic
11.2.5 North America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tracer Type
11.2.5.1 North America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tc-99m
11.2.6 North America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by End User
11.2.7 North America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Country
11.2.7.1 United States: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.2.7.1.1 United States: Radiopharmaceuticals Market Breakdown, by Application
11.2.7.1.2 United States: Radiopharmaceuticals Market Breakdown, by Type
11.2.7.1.2.1 United States: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.2.7.1.2.2 United States: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.2.7.1.3 United States: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.2.7.1.3.1 United States: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.2.7.1.4 United States: Radiopharmaceuticals Market Breakdown, by End User
11.2.7.2 Canada: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.2.7.2.1 Canada: Radiopharmaceuticals Market Breakdown, by Application
11.2.7.2.2 Canada: Radiopharmaceuticals Market Breakdown, by Type
11.2.7.2.2.1 Canada: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.2.7.2.2.2 Canada: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.2.7.2.3 Canada: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.2.7.2.3.1 Canada: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.2.7.2.4 Canada: Radiopharmaceuticals Market Breakdown, by End User
11.2.7.3 Mexico: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.2.7.3.1 Mexico: Radiopharmaceuticals Market Breakdown, by Application
11.2.7.3.2 Mexico: Radiopharmaceuticals Market Breakdown, by Type
11.2.7.3.2.1 Mexico: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.2.7.3.2.2 Mexico: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.2.7.3.3 Mexico: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.2.7.3.3.1 Mexico: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.2.7.3.4 Mexico: Radiopharmaceuticals Market Breakdown, by End User
11.3 Europe
11.3.1 Europe Radiopharmaceuticals Market Overview
11.3.2 Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3 Europe: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Application
11.3.4 Europe: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Type
11.3.4.1 Europe: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Diagnostic
11.3.4.2 Europe: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Therapeutic
11.3.5 Europe: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tracer Type
11.3.5.1 Europe: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tc-99m
11.3.6 Europe: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by End User
11.3.7 Europe: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Country
11.3.7.1 Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.1.1 Germany: Radiopharmaceuticals Market Breakdown, by Application
11.3.7.1.2 Germany: Radiopharmaceuticals Market Breakdown, by Type
11.3.7.1.2.1 Germany: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.3.7.1.2.2 Germany: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.3.7.1.3 Germany: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.3.7.1.3.1 Germany: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.3.7.1.4 Germany: Radiopharmaceuticals Market Breakdown, by End User
11.3.7.2 United Kingdom: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.2.1 United Kingdom: Radiopharmaceuticals Market Breakdown, by Application
11.3.7.2.2 United Kingdom: Radiopharmaceuticals Market Breakdown, by Type
11.3.7.2.2.1 United Kingdom: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.3.7.2.2.2 United Kingdom: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.3.7.2.3 United Kingdom: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.3.7.2.3.1 United Kingdom: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.3.7.2.4 United Kingdom: Radiopharmaceuticals Market Breakdown, by End User
11.3.7.3 France: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.3.1 France: Radiopharmaceuticals Market Breakdown, by Application
11.3.7.3.2 France: Radiopharmaceuticals Market Breakdown, by Type
11.3.7.3.2.1 France: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.3.7.3.2.2 France: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.3.7.3.3 France: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.3.7.3.3.1 France: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.3.7.3.4 France: Radiopharmaceuticals Market Breakdown, by End User
11.3.7.4 Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.4.1 Italy: Radiopharmaceuticals Market Breakdown, by Application
11.3.7.4.2 Italy: Radiopharmaceuticals Market Breakdown, by Type
11.3.7.4.2.1 Italy: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.3.7.4.2.2 Italy: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.3.7.4.3 Italy: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.3.7.4.3.1 Italy: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.3.7.4.4 Italy: Radiopharmaceuticals Market Breakdown, by End User
11.3.7.5 Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.5.1 Spain: Radiopharmaceuticals Market Breakdown, by Application
11.3.7.5.2 Spain: Radiopharmaceuticals Market Breakdown, by Type
11.3.7.5.2.1 Spain: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.3.7.5.2.2 Spain: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.3.7.5.3 Spain: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.3.7.5.3.1 Spain: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.3.7.5.4 Spain: Radiopharmaceuticals Market Breakdown, by End User
11.3.7.6 Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.3.7.6.1 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Application
11.3.7.6.2 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Type
11.3.7.6.2.1 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.3.7.6.2.2 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.3.7.6.3 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.3.7.6.3.1 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.3.7.6.4 Rest of Europe: Radiopharmaceuticals Market Breakdown, by End User
11.4 Asia Pacific
11.4.1 Asia Pacific Radiopharmaceuticals Market Overview
11.4.2 Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.4.2.1 Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Application
11.4.2.2 Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Type
11.4.2.2.1 Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Diagnostic
11.4.2.2.2 Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Therapeutic
11.4.2.3 Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tracer Type
11.4.2.3.1 Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tc-99m
11.4.2.4 Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by End User
11.4.3 Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Country
11.4.3.1 China: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.1.1 China: Radiopharmaceuticals Market Breakdown, by Application
11.4.3.1.2 China: Radiopharmaceuticals Market Breakdown, by Type
11.4.3.1.2.1 China: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.4.3.1.2.2 China: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.4.3.1.3 China: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.4.3.1.3.1 China: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.4.3.1.4 China: Radiopharmaceuticals Market Breakdown, by End User
11.4.3.2 Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.2.1 Japan: Radiopharmaceuticals Market Breakdown, by Application
11.4.3.2.2 Japan: Radiopharmaceuticals Market Breakdown, by Type
11.4.3.2.2.1 Japan: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.4.3.2.2.2 Japan: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.4.3.2.3 Japan: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.4.3.2.3.1 Japan: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.4.3.2.4 Japan: Radiopharmaceuticals Market Breakdown, by End User
11.4.3.3 India: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.3.1 India: Radiopharmaceuticals Market Breakdown, by Application
11.4.3.3.2 India: Radiopharmaceuticals Market Breakdown, by Type
11.4.3.3.2.1 India: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.4.3.3.2.2 India: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.4.3.3.3 India: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.4.3.3.3.1 India: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.4.3.3.4 India: Radiopharmaceuticals Market Breakdown, by End User
11.4.3.4 Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.4.1 Australia: Radiopharmaceuticals Market Breakdown, by Application
11.4.3.4.2 Australia: Radiopharmaceuticals Market Breakdown, by Type
11.4.3.4.2.1 Australia: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.4.3.4.2.2 Australia: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.4.3.4.3 Australia: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.4.3.4.3.1 Australia: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.4.3.4.4 Australia: Radiopharmaceuticals Market Breakdown, by End User
11.4.3.5 South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.5.1 South Korea: Radiopharmaceuticals Market Breakdown, by Application
11.4.3.5.2 South Korea: Radiopharmaceuticals Market Breakdown, by Type
11.4.3.5.2.1 South Korea: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.4.3.5.2.2 South Korea: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.4.3.5.3 South Korea: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.4.3.5.3.1 South Korea: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.4.3.5.4 South Korea: Radiopharmaceuticals Market Breakdown, by End User
11.4.3.6 Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.6.1 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Application
11.4.3.6.2 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Type
11.4.3.6.2.1 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.4.3.6.2.2 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.4.3.6.3 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.4.3.6.3.1 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.4.3.6.4 Rest of APAC: Radiopharmaceuticals Market Breakdown, by End User
11.5 Middle East and Africa
11.5.1 Middle East and Africa Radiopharmaceuticals Market Overview
11.5.2 Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.5.2.1 Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Application
11.5.2.2 Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Type
11.5.2.2.1 Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Diagnostic
11.5.2.2.2 Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Therapeutic
11.5.2.3 Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tracer Type
11.5.2.3.1 Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tc-99m
11.5.2.4 Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by End User
11.5.3 Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Country
11.5.3.1 Saudi Arabia: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.5.3.1.1 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Application
11.5.3.1.2 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Type
11.5.3.1.2.1 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.5.3.1.2.2 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.5.3.1.3 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.5.3.1.3.1 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.5.3.1.4 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by End User
11.5.3.2 South Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.5.3.2.1 South Africa: Radiopharmaceuticals Market Breakdown, by Application
11.5.3.2.2 South Africa: Radiopharmaceuticals Market Breakdown, by Type
11.5.3.2.2.1 South Africa: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.5.3.2.2.2 South Africa: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.5.3.2.3 South Africa: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.5.3.2.3.1 South Africa: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.5.3.2.4 South Africa: Radiopharmaceuticals Market Breakdown, by End User
11.5.3.3 United Arab Emirates: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.5.3.3.1 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Application
11.5.3.3.2 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Type
11.5.3.3.2.1 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.5.3.3.2.2 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.5.3.3.3 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.5.3.3.3.1 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.5.3.3.4 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by End User
11.5.3.4 Rest of Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.5.3.4.1 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Application
11.5.3.4.2 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Type
11.5.3.4.2.1 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.5.3.4.2.2 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.5.3.4.3 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.5.3.4.3.1 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.5.3.4.4 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by End User
11.6 South and Central America
11.6.1 South and Central America Radiopharmaceuticals Market Overview
11.6.2 South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.6.2.1 South and Central America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Application
11.6.2.2 South and Central America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Type
11.6.2.2.1 South and Central America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Diagnostic
11.6.2.2.2 South and Central America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Therapeutic
11.6.2.3 South and Central America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tracer Type
11.6.2.3.1 South and Central America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Tc-99m
11.6.2.4 South and Central America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by End User
11.6.3 South and Central America: Radiopharmaceuticals Market – Revenue and Forecast Analysis – by Country
11.6.3.1 Brazil: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.6.3.1.1 Brazil: Radiopharmaceuticals Market Breakdown, by Application
11.6.3.1.2 Brazil: Radiopharmaceuticals Market Breakdown, by Type
11.6.3.1.2.1 Brazil: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.6.3.1.2.2 Brazil: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.6.3.1.3 Brazil: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.6.3.1.3.1 Brazil: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.6.3.1.4 Brazil: Radiopharmaceuticals Market Breakdown, by End User
11.6.3.2 Argentina: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.6.3.2.1 Argentina: Radiopharmaceuticals Market Breakdown, by Application
11.6.3.2.2 Argentina: Radiopharmaceuticals Market Breakdown, by Type
11.6.3.2.2.1 Argentina: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.6.3.2.2.2 Argentina: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.6.3.2.3 Argentina: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.6.3.2.3.1 Argentina: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.6.3.2.4 Argentina: Radiopharmaceuticals Market Breakdown, by End User
11.6.3.3 Rest of South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
11.6.3.3.1 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Application
11.6.3.3.2 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Type
11.6.3.3.2.1 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Diagnostic
11.6.3.3.2.2 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Therapeutic
11.6.3.3.3 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Tracer Type
11.6.3.3.3.1 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Tc-99m
11.6.3.3.4 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by End User
12. Radiopharmaceuticals Market-Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Radiopharmaceuticals Market
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. Company Profiles
13.1 Cardinal Health Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Curium
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 General Electric Co
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Medi-Radiopharma
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Rotem Industries Ltd
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 ABX advanced biochemical compounds GmbH
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Invicro LLC
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Newcastle University
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Novartis AG
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Blue Earth Diagnostics Limited
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 IBA Radiopharma Solutions
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
14. Appendix
14.1 About the Research Team
14.2 Glossary of Terms

LIST OF TABLES

Table 1. Radiopharmaceuticals Market Segmentation
Table 2. Regional Pricing Analysis, US$ (Per Dose), 2023
Table 3. Ongoing Targeted Alpha Therapy Clinical Trials
Table 4. Physical Half-Lives of Some Medical Radionuclides for Diagnostic and Therapeutic Use
Table 5. Some Other Radionuclides Used in Diagnostic Radiopharmaceuticals
Table 6. Some Other Radionuclides Used in Therapeutic Radiopharmaceuticals
Table 7. Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – By Diagnostic
Table 8. Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – By Therapeutic
Table 9. Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – By Tc-99m
Table 10. North America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 11. North America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 12. North America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 13. North America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 14. North America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 15. North America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 16. North America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 17. United States: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 18. United States: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 19. United States: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 20. United States: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 21. United States: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 22. United States: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 23. United States: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 24. Canada: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 25. Canada: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 26. Canada: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 27. Canada: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 28. Canada: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 29. Canada: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 30. Canada: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 31. Mexico: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 32. Mexico: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 33. Mexico: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 34. Mexico: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 35. Mexico: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 36. Mexico: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 37. Mexico: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 38. Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 39. Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 40. Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 41. Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 42. Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 43. Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 44. Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 45. Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 46. Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 47. Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 48. Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 49. Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 50. Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 51. Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 52. United Kingdom: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 53. United Kingdom: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 54. United Kingdom: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 55. United Kingdom: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 56. United Kingdom: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 57. United Kingdom: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 58. United Kingdom: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 59. France: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 60. France: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 61. France: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 62. France: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 63. France: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 64. France: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 65. France: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 66. Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 67. Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 68. Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 69. Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 70. Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 71. Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 72. Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 73. Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 74. Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 75. Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 76. Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 77. Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 78. Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 79. Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 80. Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 81. Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 82. Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 83. Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 84. Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 85. Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 86. Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 87. Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 88. Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 89. Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 90. Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 91. Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 92. Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 93. Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 94. China: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 95. China: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 96. China: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 97. China: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 98. China: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 99. China: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 100. China: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 101. Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 102. Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 103. Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 104. Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 105. Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 106. Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 107. Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 108. India: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 109. India: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 110. India: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 111. India: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 112. India: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 113. India: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 114. India: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 115. Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 116. Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 117. Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 118. Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 119. Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 120. Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 121. Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 122. South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 123. South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 124. South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 125. South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 126. South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 127. South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 128. South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 129. Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 130. Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 131. Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 132. Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 133. Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 134. Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 135. Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 136. Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 137. Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 138. Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 139. Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 140. Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 141. Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 142. Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 143. Saudi Arabia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 144. Saudi Arabia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 145. Saudi Arabia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 146. Saudi Arabia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 147. Saudi Arabia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 148. Saudi Arabia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 149. Saudi Arabia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 150. South Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 151. South Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 152. South Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 153. South Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 154. South Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 155. South Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 156. South Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 157. United Arab Emirates: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 158. United Arab Emirates: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 159. United Arab Emirates: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 160. United Arab Emirates: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 161. United Arab Emirates: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 162. United Arab Emirates: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 163. United Arab Emirates: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 164. Rest of Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 165. Rest of Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 166. Rest of Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 167. Rest of Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 168. Rest of Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 169. Rest of Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 170. Rest of Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 171. South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 172. South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 173. South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 174. South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 175. South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 176. South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 177. South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 178. Brazil: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 179. Brazil: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 180. Brazil: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 181. Brazil: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 182. Brazil: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 183. Brazil: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 184. Brazil: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 185. Argentina: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 186. Argentina: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 187. Argentina: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 188. Argentina: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 189. Argentina: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 190. Argentina: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 191. Argentina: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 192. Rest of South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 193. Rest of South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Type
Table 194. Rest of South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Diagnostic
Table 195. Rest of South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic
Table 196. Rest of South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tracer Type
Table 197. Rest of South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by Tc-99m
Table 198. Rest of South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 199. Recent Inorganic Growth Strategies in the Radiopharmaceuticals Market
Table 200. Recent Organic Growth Strategies in the Radiopharmaceuticals Market
Table 201. Glossary of Terms, Radiopharmaceuticals Market

LIST OF FIGURES

Figure 1. Radiopharmaceuticals Market Segmentation, by Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Radiopharmaceuticals Market Revenue (US$ Million), 2023–2031
Figure 5. Bioprocessing Market Breakdown by Geography, 2023 and 2031 (%)
Figure 6. Radiopharmaceuticals Market Share (%) – by Application (2023 and 2031)
Figure 7. Oncology: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. Cardiology: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 9. Neurology: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 10. Pulmonary: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 11. Urology: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 12. Others: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Radiopharmaceuticals Market Share (%) – by Type (2023 and 2031)
Figure 14. Diagnostic: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 15. Therapeutic: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 16. Radiopharmaceuticals Market Share (%) – by Tracer Type (2023 and 2031)
Figure 17. Tc-99m: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 18. F-18: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 19. Ga-68: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 20. TL-201: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 21. I-131: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 22. Fe-59: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 23. Lu-171: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 24. RB-82 and N-13: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 25. Cr-51 and P-32: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 26. Sc-46: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 27. Sg-269 and Hs-269: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 28. Others: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 29. Radiopharmaceuticals Market Share (%) – by End User (2023 and 2031)
Figure 30. Hospitals and Clinics: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 31. Diagnostic Centers: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 32. Academic and Research Institutes: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 33. Others: Radiopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Million)
Figure 34. Radiopharmaceuticals Market Breakdown by Region, 2023 and 2031 (%)
Figure 35. North America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 36. North America: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 37. United States: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 38. Canada: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 39. Mexico: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 40. Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 41. Europe: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 42. Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 43. United Kingdom: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 44. France: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 45. Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 46. Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 47. Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 48. Asia Pacific: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 49. Asia Pacific: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 50. China: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 51. Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 52. India: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 53. Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 54. South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 55. Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 56. Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 57. Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 58. Saudi Arabia: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 59. South Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 60. United Arab Emirates: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 61. Rest of Middle East and Africa: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 62. South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 63. South and Central America: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 64. Brazil: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 65. Argentina: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 66. Rest of South and Central America: Radiopharmaceuticals Market – Revenue and Forecast to 2031(US$ Million)
Figure 67. Growth Strategies in the Radiopharmaceuticals Market

The List of Companies – Radiopharmaceuticals Market
o Medi-Radiopharma (MRP)
o Rotem Industries Ltd.
o ABX Advanced Biochemical Compounds GmbH
o Invicro LLC
o Cardinal Health
o Newcastle University
o Novartis
o Curium
o Blue Earth Diagnostics
o General Electric Company
o IBA Radiopharma Solutions

Reviews

There are no reviews yet.

Be the first to review “Radiopharmaceuticals Market Size and Forecast (2021-2031)”